Phase 3 Type 1 Diabetes Trial, Recruiting (NCT06894784)

Phase 3 Type 1 Diabetes Trial, Recruiting NCT06894784 Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Condition: Type 1 Diabetes

Printed from Voxsanity (voxsanity.com.au) — NCT06894784 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Type 1 Diabetes

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 18 years old or older (any gender)
You have been diagnosed with Type 1 diabetes for at least one year
You have been using an automated insulin delivery (AID) system — sometimes called a "closed-loop" or "artificial pancreas" system — for at least three months
Your Body Mass Index (BMI) is 23 or higher (confirm with trial site if unsure of your BMI)

Who may not be able to join:

You have taken a GLP-1 receptor agonist medication (such as semaglutide or liraglutide) within the past month
You have taken an SGLT2 inhibitor medication (such as empagliflozin or dapagliflozin) within the past two weeks
You are currently pregnant or planning to become pregnant
You are currently breastfeeding
You have had a severe low blood sugar episode in the past three months — meaning a very low blood sugar that caused a seizure, loss of consciousness, or a visit to the emergency department
You have had a diabetic ketoacidosis (DKA) episode within the past six months
You have a history of acute pancreatitis, chronic pancreatitis, or gallbladder disease
You or a close family member has a history of a specific type of thyroid cancer (medullary thyroid cancer) or a condition called multiple endocrine neoplasia type 2
Your kidneys are not functioning well enough, based on a blood test result taken within the past four months (confirm with trial site)
You have significant diabetes-related eye disease or stomach-emptying problems, as judged by the study doctor
You have had weight-loss (bariatric) surgery within the past six months
You have a serious medical or psychiatric condition that the study doctor believes would make it difficult for you to participate
You are unable or unwilling to manage your diabetes safely, as judged by the study doctor

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 15 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Dr. Michael Tsoukas, Division of Endocrinology and Metabolism - McGill University Health Center

Phone: 438-531-6896

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06894784

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Phase: Phase 3

Status: Recruiting

Condition: Type 1 Diabetes

Trial contact: 438-531-6896

More information: https://clinicaltrials.gov/study/NCT06894784

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 18 years old or older (any gender)
You have been diagnosed with Type 1 diabetes for at least one year
You have been using an automated insulin delivery (AID) system — sometimes called a "closed-loop" or "artificial pancreas" system — for at least three months
Your Body Mass Index (BMI) is 23 or higher (confirm with trial site if unsure of your BMI)

Who may not be able to join:

You have taken a GLP-1 receptor agonist medication (such as semaglutide or liraglutide) within the past month
You have taken an SGLT2 inhibitor medication (such as empagliflozin or dapagliflozin) within the past two weeks
You are currently pregnant or planning to become pregnant
You are currently breastfeeding
You have had a severe low blood sugar episode in the past three months — meaning a very low blood sugar that caused a seizure, loss of consciousness, or a visit to the emergency department
You have had a diabetic ketoacidosis (DKA) episode within the past six months
You have a history of acute pancreatitis, chronic pancreatitis, or gallbladder disease
You or a close family member has a history of a specific type of thyroid cancer (medullary thyroid cancer) or a condition called multiple endocrine neoplasia type 2
Your kidneys are not functioning well enough, based on a blood test result taken within the past four months (confirm with trial site)
You have significant diabetes-related eye disease or stomach-emptying problems, as judged by the study doctor
You have had weight-loss (bariatric) surgery within the past six months
You have a serious medical or psychiatric condition that the study doctor believes would make it difficult for you to participate
You are unable or unwilling to manage your diabetes safely, as judged by the study doctor

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 15 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Registry

ClinicalTrials.gov

Start date

1 April 2025

Est. completion

1 January 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Time-in-Range

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov